Moberg Pharma AB (publ)
STO:MOB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.645
38.92
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Moberg Pharma AB (publ)
Moberg Pharma AB (publ)
Other Current Assets
Moberg Pharma AB (publ)
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Moberg Pharma AB (publ)
STO:MOB
|
Other Current Assets
kr1m
|
CAGR 3-Years
-81%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Calliditas Therapeutics AB
STO:CALTX
|
Other Current Assets
kr94.4m
|
CAGR 3-Years
115%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Camurus AB
STO:CAMX
|
Other Current Assets
kr90.3m
|
CAGR 3-Years
120%
|
CAGR 5-Years
58%
|
CAGR 10-Years
N/A
|
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Other Current Assets
kr63.8m
|
CAGR 3-Years
55%
|
CAGR 5-Years
99%
|
CAGR 10-Years
N/A
|
|
|
IRLAB Therapeutics AB
STO:IRLAB A
|
Other Current Assets
kr3.1m
|
CAGR 3-Years
15%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Other Current Assets
kr12.4m
|
CAGR 3-Years
20%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
Moberg Pharma AB (publ)
Glance View
Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. The company is headquartered in Bromma, Stockholm. The company went IPO on 2011-05-26. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The firm collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. The company is active in more than 35 countries, and operates, among others, through Alterna LLC. The company also owns three Over-The-Counter (OTC) brands in the United States.
See Also
What is Moberg Pharma AB (publ)'s Other Current Assets?
Other Current Assets
1m
SEK
Based on the financial report for Dec 31, 2023, Moberg Pharma AB (publ)'s Other Current Assets amounts to 1m SEK.
What is Moberg Pharma AB (publ)'s Other Current Assets growth rate?
Other Current Assets CAGR 3Y
-81%
Over the last year, the Other Current Assets growth was 34%. The average annual Other Current Assets growth rates for Moberg Pharma AB (publ) have been -81% over the past three years .
You don't have any saved screeners yet
